This Dividend Stock Has Plunged Ahead of Trump’s Inauguration. Here Are 3 Reasons Investors Should Still Buy It.

There has been a shakeup in markets since Donald Trump’s election, and investors have been positioning their portfolios to bet on names that are expected to benefit from the incoming president’s policies. The pharma and healthcare space, which was already out of favor with investors, has continued to look weak after the president-elect tapped Robert F. Kennedy, Jr. to head the Department of Health and Human Services.

A known vaccine skeptic, Kennedy’s anointment led to a selloff in vaccine makers’ share prices. Global pharma giant Pfizer (PFE), which fell 10% in 2022 and 41% in 2023, ended 2024 down about 2%. Pfizer stock trades in the ballpark of $26 and fell to a multi-year low last year before recovering slightly. In this article, we’ll discuss why Pfizer’s stock is so low and whether it is a buy or sell now as Trump takes office in just a few days.